Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$9.13 +0.66%

+$0.13 today

Market cap
$821.96M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.30M

Average 1.70M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$322.98M

FY 2025 · Annual

Investing Cash Flow

$290.04M

FY 2025 · Annual

Financing Cash Flow

$13.68M

FY 2025 · Annual

-96.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Depreciation & Amortization43K33K12K8K6K
Deferred Income Tax255K0000
Stock-Based Compensation13.32M16.02M30.95M43.03M47.5M
Change in Working Capital(9.6M)1.66M31.86M13.27M(79.32M)
Accounts Receivables0(3.47M)10.71M(11.24M)(36.83M)
Inventory03.47M0(366K)(32.09M)
Accounts Payables2.16M(1.32M)5.61M1.67M4.95M
Other Working Capital(11.76M)2.98M15.54M23.21M(15.35M)
Other Non-Cash Items187K(2.05M)(14.06M)(12.45M)(5.75M)
Operating Cash Flow29.13M(133.68M)(160.6M)(274.9M)(322.98M)
Capital Expenditures(129K)(225K)00(187K)
Acquisitions (Net)40.74K225K000
Purchases of Investments(294.72M)(495.35M)(354.61M)(557.05M)(195.81M)
Sales of Investments253.98M308.93M472.22M337.28M486.03M
Other Investing Activities(40.74K)225K000
Investing Cash Flow(40.87M)(186.19M)117.61M(219.78M)290.04M
Debt Repayment0(21M)000
Common Stock Issued86.34M181.39M258.09M9.72M13.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities32.13M11.86M6.04M343.65M0
Financing Cash Flow118.46M172.25M264.13M353.37M13.68M
Effect of Forex Changes00000
Net Change in Cash106.72M(147.61M)221.14M(141.31M)(19.27M)
Free Cash Flow29M(133.9M)(160.6M)(274.9M)(323.17M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$285.4M
+ D&A$6.0K
+ Stock-Based Comp$47.5M
+ Deferred Tax$0
- Working Capital-$79.3M
- Other Non-Cash-$5.7M
= Operating Cash Flow-$323.0M
- Capex-$187.0K
= Free Cash Flow-$323.2M

Analysis

FY2025 free cash flow is -$323.2M. FCF conversion is 113.2% of net income. Operating cash flow was -$323.0M, with capex of -$187.0K. The largest bridge item is Working Capital at -$79.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
3Initial statement of beneficial ownershipNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 2, 2026
8-KCurrent reportNov 2, 2026

Does SNDX generate free cash flow?

Syndax Pharmaceuticals, Inc. (SNDX) generated -$323.17M of free cash flow in fiscal 2025.

How much operating cash flow does SNDX produce?

Operating cash flow was -$322.98M, before capital expenditures of $187,000.00.